Titanium Dioxide – CLP Classification – ECJ Annulment of the Classification as Carcinogenic Substance by Inhalation Titanium Dioxide – CLP Classification – ECJ Annulment of the Classification as Carcinogenic Substance by Inhalation The Court of Justice... Titanium Dioxide – CLP Classification – ECJ Annulment of the Classification as Carcinogenic Substance by Inhalation
MHRA Nitrosamines – Step 2 – Risk Assessment and Confirmatory Testing Links Updated MHRA Nitrosamines – Medicines: Marketing Authorisation Holders’ submission of Nitrosamine risk evaluation, risk assessment and confirmatory testing updated MHRA has... MHRA Nitrosamines – Step 2 – Risk Assessment and Confirmatory Testing Links Updated
EMA Summary Report of ISG Meeting on EMA’s Extended Mandate EMA Summary Report of ISG Meeting on EMA’s Extended Mandate The European Medicines Agency (EMA) has published its summary report... EMA Summary Report of ISG Meeting on EMA’s Extended Mandate
MHRA Guidance on Borderline Products Updated MHRA Guidance on Borderline Products Updated The MHRA has updated their guidance ‘Borderline products: how to tell if your product... MHRA Guidance on Borderline Products Updated
CMDh November 2022 Meeting – Report CMDh November 2022 Meeting – Report The Co-ordination group for Mutual recognition and Decentralised procedures – human (CMDh) has published... CMDh November 2022 Meeting – Report
EMA System Demo: Q&A Documents Published EMA System Demo: Q&A Documents Published Following up on the three System Demos that took place in March, June and... EMA System Demo: Q&A Documents Published
MHRA Publishes Access Consortium Good Manufacturing Practice (GMP) Statement MHRA Publishes Access Consortium Good Manufacturing Practice (GMP) Statement In alignment with the Access Consortium’s strategic objective to expand and... MHRA Publishes Access Consortium Good Manufacturing Practice (GMP) Statement
MHRA Consultation on Proposals to Increase Statutory Fees – PAGB Response MHRA Consultation on Proposals to Increase Statutory Fees – PAGB Response MHRA is seeking views on proposals for changes to... MHRA Consultation on Proposals to Increase Statutory Fees – PAGB Response
HMPWG Meeting Report – May 2022 HMPWG Meeting Report – May 2022 The Heads of Medicines Agencies (HMA) Homeopathic Medicinal Products Working Group (HMPWG) has published... HMPWG Meeting Report – May 2022
EMRN Webinar – Draft Data Quality Framework for EU Medicines Regulation EMRN Webinar – Draft Data Quality Framework for EU Medicines Regulation The European Medicines Regulatory Network (EMRN) has... EMRN Webinar – Draft Data Quality Framework for EU Medicines Regulation
Draft EU Monograph on Fumaria officinalis L., herba – Consultation Draft EU Monograph on Fumaria officinalis L., herba – Consultation Further to its adoption by the EMA Committee on Herbal... Draft EU Monograph on Fumaria officinalis L., herba – Consultation
MHRA Guidance on Pharmacovigilance Procedures Updated MHRA Guidance on Pharmacovigilance Procedures Updated The MHRA has updated their guidance on Pharmacovigilance Procedures which summarises MHRA’s approach to... MHRA Guidance on Pharmacovigilance Procedures Updated
